Charles Schwab’s Puma Biotechnology PBYI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.04M Buy
128,243
+12,328
+11% +$90.3K ﹤0.01% 2997
2026
Q1
$741K Sell
115,915
-9,457
-8% -$61K ﹤0.01% 2991
2025
Q4
$746K Hold
125,372
﹤0.01% 3021
2025
Q3
$666K Sell
125,372
-2,071
-2% -$8.78K ﹤0.01% 3077
2025
Q2
$437K Buy
127,443
+9,189
+8% +$29.3K ﹤0.01% 3181
2025
Q1
$350K Buy
118,254
+588
+0.5% +$1.84K ﹤0.01% 3168
2024
Q4
$359K Hold
117,666
﹤0.01% 3236
2024
Q3
$300K Sell
117,666
-8,574
-7% -$26K ﹤0.01% 3283
2024
Q2
$412K Buy
126,240
+106,787
+549% +$469K ﹤0.01% 3273
2024
Q1
$103K Hold
19,453
﹤0.01% 3304
2023
Q4
$84.2K Hold
19,453
﹤0.01% 3359
2023
Q3
$51.2K Hold
19,453
﹤0.01% 3406
2023
Q2
$68.7K Hold
19,453
﹤0.01% 3380
2023
Q1
$60.1K Hold
19,453
﹤0.01% 3322
2022
Q4
$82.3K Buy
+19,453
New +$67.1K ﹤0.01% 3286
2022
Q3
Sell
-28,820
Closed -$83K 3539
2022
Q2
$83K Sell
28,820
-46,174
-62% -$115K ﹤0.01% 3304
2022
Q1
$216K Sell
74,994
-5,658
-7% -$14.6K ﹤0.01% 3294
2021
Q4
$246K Hold
80,652
﹤0.01% 3328
2021
Q3
$566K Sell
80,652
-199,023
-71% -$1.49M ﹤0.01% 3104
2021
Q2
$2.57M Buy
279,675
+11,719
+4% +$119K ﹤0.01% 2626
2021
Q1
$2.6M Sell
267,956
-60,020
-18% -$670K ﹤0.01% 2588
2020
Q4
$3.37M Buy
327,976
+5,731
+2% +$58K ﹤0.01% 2410
2020
Q3
$3.25M Sell
322,245
-252
-0.1% -$2.57K ﹤0.01% 2291
2020
Q2
$3.36M Buy
322,497
+12,735
+4% +$132K ﹤0.01% 2212
2020
Q1
$2.62M Sell
309,762
-28,027
-8% -$272K ﹤0.01% 2157
2019
Q4
$2.96M Sell
337,789
-11,049
-3% -$91.5K ﹤0.01% 2284
2019
Q3
$3.76M Buy
348,838
+167,331
+92% +$1.81M ﹤0.01% 2121
2019
Q2
$2.31M Buy
181,507
+7,216
+4% +$166K ﹤0.01% 2323
2019
Q1
$6.76M Buy
174,291
+12,580
+8% +$384K ﹤0.01% 1826
2018
Q4
$3.29M Sell
161,711
-1,833
-1% -$55K ﹤0.01% 2126
2018
Q3
$7.5M Buy
163,544
+3,150
+2% +$152K 0.01% 1817
2018
Q2
$9.49M Buy
160,394
+9,813
+7% +$569K 0.01% 1638
2018
Q1
$10.2M Buy
150,581
+10,383
+7% +$777K 0.01% 1474
2017
Q4
$13.9M Buy
140,198
+5,031
+4% +$563K 0.01% 1258
2017
Q3
$16.2M Buy
135,167
+11,787
+10% +$1.1M 0.01% 1080
2017
Q2
$10.8M Buy
123,380
+4,068
+3% +$228K 0.01% 1301
2017
Q1
$4.44M Buy
119,312
+6,138
+5% +$224K ﹤0.01% 1826
2016
Q4
$3.48M Buy
113,174
+21,655
+24% +$936K ﹤0.01% 1932
2016
Q3
$6.14M Sell
91,519
-13,503
-13% -$683K 0.01% 1512
2016
Q2
$3.13M Buy
105,022
+46,522
+80% +$1.45M ﹤0.01% 1847
2016
Q1
$1.72M Sell
58,500
-4,542
-7% -$205K ﹤0.01% 2129
2015
Q4
$4.94M Buy
63,042
+4,157
+7% +$326K 0.01% 1527
2015
Q3
$4.44M Buy
58,885
+27,579
+88% +$2.61M 0.01% 1553
2015
Q2
$3.65M Sell
31,306
-39,732
-56% -$7.2M 0.01% 1752
2015
Q1
$16.8M Buy
71,038
+5,024
+8% +$1.07M 0.02% 648
2014
Q4
$12.5M Buy
66,014
+1,337
+2% +$297K 0.02% 749
2014
Q3
$15.4M Sell
64,677
-867
-1% -$178K 0.03% 583
2014
Q2
$4.33M Buy
65,544
+2,298
+4% +$163K 0.01% 1521
2014
Q1
$6.59M Buy
63,246
+6,897
+12% +$811K 0.01% 1105
2013
Q4
$5.83M Buy
56,349
+2,013
+4% +$118K 0.01% 1133
2013
Q3
$3.03M Buy
54,336
+13,717
+34% +$739K 0.01% 1571
2013
Q2
$1.93M Buy
+40,619
New +$1.43M ﹤0.01% 1782

Other funds holding PBYI

Charles Schwab's PBYI Position: Q2 2026 in Review

Charles Schwab increased its Puma Biotechnology (PBYI) stake by 11% in Q2 2026, buying an estimated $90.3K and bringing the position to 128,243 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #2997.

Charles Schwab first reported a position in PBYI in Q2 2013 and has held it in 52 quarters since. The position peaked at $16.8M in Q1 2015. 161 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • Charles Schwab held 128,243 shares of Puma Biotechnology worth $1.04M as of Q2 2026.
  • Charles Schwab bought 12,328 Puma Biotechnology shares in Q2 2026, an estimated $90.3K.
  • Puma Biotechnology made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2997 holding.
  • Charles Schwab first reported a position in Puma Biotechnology in Q2 2013 and has held it in 52 quarters since.
  • Charles Schwab's Puma Biotechnology position peaked at $16.8M in Q1 2015.
  • 161 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.